ZS Pharma Announces Participation at Upcoming Investor Conferences

REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that management will present at the following investor conferences next month:

The presentations will be webcast live and available for replay from ZS Pharma's website at http://www.zspharma.com in the Investor Relations section. A replay of the webcasts will be available on the Company's website for 30 days following the live event.

About ZS Pharma

ZS Pharma is a publicly traded (Nasdaq: ZSPH), biopharmaceutical company with offices in Redwood City, California and Coppell, Texas. ZS Pharma's lead therapeutic candidate, ZS-9 (sodium zirconium cyclosilicate), is an investigational treatment for hyperkalemia that is being evaluated in late-stage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels. ZS Pharma is also pursuing the discovery of additional drug candidates that utilize its novel selective ion-trap technology for the treatment of kidney and liver diseases. Additional information about ZS Pharma is available at www.zspharma.com.

CONTACT: ZS Pharma Contacts
         Adam Tomasi (Investors)
         ZS Pharma
         650.458.4100
         [email protected]

         Denise Powell (Media)
         Red House Consulting
         510.703.9491
         [email protected]

You May Also Be Interested In

• Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy
• IRG, PREP Funds, CG Real Estate Capital Acquire Three-Property Industrial Portfolio in Sale-Leaseback Transaction with Anchor Manufacturing
• Crypto News: Pepeto Announces Increased Investments Following Dogecoin Success While the Bitcoin Price Prediction Targets $1.2 Million